Cadrenal Therapeutics, Inc.CVKD

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · cadrenal.com

Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions. Its pipeline includes CAD-1005, a novel 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia and Cardiac Surgery-Associated Acute Kidney Injury, plus tecarfarin, a late-stage oral vitamin K antagonist for patients requiring chronic anticoagulation, and frunexian.

Key ratios

ROA

-125.9%TTM

2025 -116.4%2024 -73.5%2023 -102.6%

ROE

-275.2%TTM

2025 -260.1%2024 -140.8%2023 -780.6%

Recent news

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference 2026-09-03 · GlobeNewswire Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia 2026-08-31 · GlobeNewswire

Track CVKD in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer